Table 2.

ORs (95% CI) of achieving sustained VLDA and DAPSA remission according to the baseline variable values

	VLDA		DAPSA remission
	OR (95% CI)	P value	OR (95% CI)	P value
Gender  Male vs. female	1.02 (0.31–3.3)	n.s.	3.23 (1.1–9.4)	< 0.05
Age  ≤ 50 years vs.  > 50 years	1.69 (0.54–5.11)	n.s.	1.74 (0.56–5.23)	n.s.
Disease duration  ≤ 2 years vs.  > 2 years	4.95 (1.44–16.9)	< 0.01	3.17 (1.02–9.8)	< 0.05
Enthesitis  Absence vs.  presence	1.3 (0.37–4.5)	n.s.	0.61 (0.34–1.14)	n.s.
BMI  < 30 vs.  ≥ 30	1.86 (0.54–6.4)	n.s.	1.75 (0.52–6.2)	n.s.
HAQ  ≤ 0.5 vs.  VAS > 0.5	2.6 (0.75–8.9)	n.s.	1.9 (0.63–5.7)	n.s.
CRP  ≤ 0.5 vs.  VAS > 0.5	0.22 (0.06–0.74)	< 0.05	0.31 (0.1–0.95)	n.s.
PtGA  VAS ≤ 50 vs.  VAS > 50	1.15 (0.33–3.93)	n.s.	2.83 (0.87–9.16)	n.s.
Pain  VAS ≤ 50 vs.  VAS > 50	3.75 (1.1–12.8)	< 0.05	5.25 (011.5–18.4)	< 0.05
PASI  < 1 vs.  ≥ 1	1.02 (0.32–3.2)	n.s.	1.12 (0.4–4.2)	n.s.
DMARDs  Concomitant use vs.  anti-TNF monotherapy	0.39 (0.14–1.09)	n.s.	0.89 (0.77–1.23)	n.s.